e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Idiopathic pulmonary fibrosis: clinical view
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
C. Ravaglia, C. Gurioli, M. Romagnoli, G. Casoni, S. Tomassetti, C. Gurioli, V. Poletti (Forlì, Italy)
Source:
Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Session:
Idiopathic pulmonary fibrosis: clinical view
Session type:
Poster Discussion
Number:
3370
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Ravaglia, C. Gurioli, M. Romagnoli, G. Casoni, S. Tomassetti, C. Gurioli, V. Poletti (Forlì, Italy). Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series. Eur Respir J 2013; 42: Suppl. 57, 3370
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Changes in the small airways in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept